Innova Captab Limited (BOM:544067)
1,091.05
+8.45 (0.78%)
At close: Aug 21, 2026
Innova Captab Revenue
Innova Captab had revenue of 4.71B INR in the quarter ending June 30, 2026, with 33.94% growth. This brings the company's revenue in the last twelve months to 17.49B, up 34.47% year-over-year. In the fiscal year ending March 31, 2026, Innova Captab had annual revenue of 16.30B with 31.06% growth.
Revenue (ttm)
17.49B
Revenue Growth
+34.47%
P/S Ratio
3.56
Revenue / Employee
10.93M
Employees
1,600
Market Cap
62.29B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 16.30B | 3.86B | 31.06% |
| Mar 31, 2025 | 12.44B | 1.62B | 15.02% |
| Mar 31, 2024 | 10.81B | 1.55B | 16.72% |
| Mar 31, 2023 | 9.26B | 1.26B | 15.72% |
| Mar 31, 2022 | 8.01B | 3.90B | 94.94% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Viyash Scientific | 35.75B |
| Unichem Laboratories | 23.08B |
| FDC Limited | 21.90B |
| Morepen Laboratories | 19.51B |
| Sanofi India | 18.05B |
| CORONA Remedies | 14.79B |
| Procter & Gamble Health | 14.33B |
| Bliss GVS Pharma | 10.05B |